Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.
Ann Med. 2012 Jun;44(4):313-24. doi: 10.3109/07853890.2011.573498. Epub 2011 Apr 18.
Reduced HDL cholesterol, commonly found in subjects with obesity and type 2 diabetes, is associated with increased risk of cardiovascular disease (CVD). ApoA-II, a constituent apolipoprotein of certain HDL particles, plays an important role in the regulation of cholesterol efflux, HDL remodelling, and cholesteryl ester uptake via its interactions with lipid transfer proteins, lipases, and cellular HDL receptors. Recent studies have linked apoA-II directly with triglyceride and glucose metabolism. Most of the data are, however, derived from cellular systems and transgenic animal models. Direct evidence from human studies is scarce. Clinical studies demonstrate that apoA-II is a strong predictor of risk for CVD. There is no evidence, however, that selective therapeutic modification of apoA-II impacts on atherosclerosis and clinical outcomes. More research is required to investigate further the significance of apoA-II in clinical medicine.
高密度脂蛋白胆固醇（HDL 胆固醇）水平降低常见于肥胖症和 2 型糖尿病患者，与心血管疾病（CVD）风险增加相关。载脂蛋白 A-II（ApoA-II）是某些 HDL 颗粒的组成载脂蛋白，通过与脂质转运蛋白、脂肪酶和细胞 HDL 受体相互作用，在胆固醇外排、HDL 重塑和胆固醇酯摄取中发挥重要作用。最近的研究将 ApoA-II 与甘油三酯和葡萄糖代谢直接联系起来。然而，这些数据大多来自细胞系统和转基因动物模型。来自人体研究的直接证据很少。临床研究表明，ApoA-II 是 CVD 风险的一个强有力的预测指标。然而，没有证据表明选择性治疗性修饰 ApoA-II 会影响动脉粥样硬化和临床结局。需要进一步的研究来探讨 ApoA-II 在临床医学中的意义。
